Willems E W, Heiligers J P, De Vries P, Kapoor K, Tom B, Villalón C M, Saxena P R
Department of Pharmacology, Dutch Migraine Research Group and Cardiovascular Research Institute 'COEUR', Erasmus University Medical Centre Rotterdam, 3000 DR Rotterdam, The Netherlands.
Cephalalgia. 2001 Mar;21(2):110-9. doi: 10.1046/j.1468-2982.2001.00167.x.
It has recently been shown that the alpha-adrenoceptors mediating vasoconstriction of porcine carotid arteriovenous anastomoses resemble both alpha1- and alpha2-adrenoceptors, but no attempt was made to identify the specific subtypes (alpha1A, alpha1B and alpha1D) involved. Therefore, the present study was designed to elucidate the specific subtype(s) of alpha1-adrenoceptors involved in the above response, using the alpha1-adrenoceptor agonist phenylephrine and alpha1-adrenoceptor antagonists 5-methylurapidil (alpha1A), L-765 314 (alpha1B) and BMY 7378 (alpha1D). Ten-minute intracarotid infusions of phenylephrine (1, 3 and 10 microgkg-1.min-1) induced a dose-dependent decrease in total carotid and arteriovenous anastomotic conductance, accompanied by a small tachycardia. These carotid vascular effects were abolished by L-765 314 (1000 microgkg-1; i.v.), while these responses were only attenuated by 5-methylurapidil (1000 microgkg-1; i.v.), and BMY 7378 (1000 microgkg-1; i.v.). Furthermore, intravenous bolus injections of phenylephrine (3 and 10 microgkg-1) produced a dose-dependent vasopressor response, which was only affected by 1000 microgkg-1 of 5-methylurapidil, while the other antagonists were ineffective. These results, coupled to the binding affinities of the above antagonists at the different alpha1-adrenoceptors, suggest that both alpha1A- and alpha1B-adrenoceptors mediate constriction of carotid arteriovenous anastomoses in anaesthetized pigs. In view of the less ubiquitous nature of alpha1B- compared to alpha1A-adrenoceptors, the development of potent and selective alpha1B-adrenoceptor agonists may prove to be important for the treatment of migraine.
最近的研究表明,介导猪颈动脉动静脉吻合处血管收缩的α-肾上腺素能受体兼具α1和α2肾上腺素能受体的特征,但未尝试鉴定其中涉及的特定亚型(α1A、α1B和α1D)。因此,本研究旨在使用α1-肾上腺素能受体激动剂去氧肾上腺素和α1-肾上腺素能受体拮抗剂5-甲基尿嘧啶(α1A)、L-765 314(α1B)和BMY 7378(α1D)来阐明参与上述反应的α1-肾上腺素能受体的特定亚型。颈动脉内输注10分钟的去氧肾上腺素(1、3和10微克/千克·分钟-1)导致总颈动脉和动静脉吻合处的传导率呈剂量依赖性降低,并伴有轻微的心动过速。L-765 314(1000微克/千克;静脉注射)可消除这些颈动脉血管效应,而5-甲基尿嘧啶(1000微克/千克;静脉注射)和BMY 7378(1000微克/千克;静脉注射)仅能减弱这些反应。此外,静脉推注去氧肾上腺素(3和10微克/千克)产生剂量依赖性的升压反应,仅受到1000微克/千克的5-甲基尿嘧啶的影响,而其他拮抗剂则无效。这些结果,再加上上述拮抗剂在不同α1-肾上腺素能受体上的结合亲和力,表明α1A和α1B肾上腺素能受体均介导麻醉猪颈动脉动静脉吻合处的收缩。鉴于与α1A-肾上腺素能受体相比,α1B-肾上腺素能受体的分布不那么广泛,开发强效和选择性的α1B-肾上腺素能受体激动剂可能对偏头痛的治疗具有重要意义。